The Oncosearch | Oncotarget

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes Review

Vic Hart, Hannah Gautrey, John Kirby, Alison Tyson-Capper

Published Oct 22, 2020 · Vol. 11, No. 46 · pp. 4338-4357

Keywords: HER2, Δ16-HER2, splice variant, breast cancer, trastuzumab

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine Review

Niraj Lodhi, Moe Tun, Poonam Nagpal, Arati A. Inamdar, Nehad M. Ayoub, Noor Siyam, Lucia Oton-Gonzalez, Angela Gerona, Dainelle Morris, Rana Sandhu, Kwangsun Stephen Suh

Published Oct 20, 2020 · Vol. 11, No. 44 · pp. 4045-4073

Keywords: DLBCL, diagnosis, R-CHOP, precision medicine, prognosis

A systematic review and meta-analysis of selected toxicity endpoints of alpelisib Review

Misty Shields, Qianxing Mo, Melissa Armitage, Susan C. Sharpe, Ricardo L.B. Costa

Published Oct 5, 2020 · Vol. 11, No. 42 · pp. 3793-3799

Keywords: alpelisib, adverse event, hyperglycemia, rash, diarrhea

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Nathan M. Merrill, Nathalie M. Vandecan, Kathleen C. Day, Phillip L. Palmbos, Mark L. Day, Aaron M. Udager, Sofia D. Merajver, Matthew B. Soellner

Published Oct 3, 2020 · Vol. 11, No. 44 · pp. 3921-3932

Keywords: bladder cancer, drug screen, 3D culture, basal bladder cancer, MEK inhibition

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer Research Paper

Thomas M. Cardillo, Diane L. Rossi, Maria B. Zalath, Donglin Liu, Roberto Arrojo, Robert M. Sharkey, Chien-Hsing Chang, David M. Goldenberg

Published Oct 1, 2020 · Vol. 11, No. 43 · pp. 3849-3862

Keywords: sacituzumab govitecan, Trop-2, biomarker, RAD51, triple-negative breast cancer

Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment Research Paper

Gennady M. Zharinov, Oleg A. Bogomolov, Irina V. Chepurnaya, Natalia Yu. Neklasova, Vladimir N. Anisimov

Published Sep 18, 2020 · Vol. 11, No. 41 · pp. 3723-3729

Keywords: prostate cancer, overall survival, poor prognosis, melatonin

Simvastatin is a potential candidate drug in ovarian clear cell carcinomas Research Paper

Nicolai Skovbjerg Arildsen, Ingrid Hedenfalk

Published Sep 8, 2020 · Vol. 11, No. 40 · pp. 3660-3674

Keywords: ovarian clear cell cancer, simvastatin, CID-1067700, Rho GTPase, actin

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity Research Paper

Bhumika Wadhwa, Masroor Paddar, Sameer Khan, Sameer Mir, Philip A.Clarke, Anna M. Grabowska, Devanahalli G. Vijay, Fayaz Malik

Published Sep 8, 2020 · Vol. 11, No. 45 · pp. 4178-4194

Keywords: AKT isoform, CSCs, ABCG2, drug resistance, TNBCs

Targeting desmoplasia in pancreatic cancer as an essential first step to effective therapy Research Perspective

Nancy D. Ebelt, Vic Zamloot, Edwin R. Manuel

Published Sep 8, 2020 · Vol. 11, No. 38 · pp. 3486-3488

Keywords: pancreatic cancer, desmoplasia, fibrosis, hyaluronan, collagen

Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis Research Paper

Myoung Sook Kim, Ramkishore Gernapudi, Yessenia Cedeño Cedeño, Brian M. Polster, Ramon Martinez, Paul Shapiro, Santosh Kesari, Elmar Nurmemmedov, Antonino Passaniti

Published Sep 3, 2020 · Vol. 11, No. 43 · pp. 3863-3885

Keywords: mitochondrial ATP synthase, oxygen consumption rate, ATP synthesis, reactive oxygen species,

Small ceramide tames big p53 mutant beast Editorial

Ronald A. Hill, Zhijun Liu, Yong-Yu Liu

Published Sep 1, 2020 · Vol. 11, No. 37 · pp. 3418-3419

Keywords: ceramide, p53 tumor suppressor, missense mutation, nanomicelle, drug resistance

Biological evaluation of pyrazolyl-urea and dihydro-imidazo-pyrazolyl-urea derivatives as potential anti-angiogenetic agents in the treatment of neuroblastoma Research Paper

Barbara Marengo, Elda Meta, Chiara Brullo, Chiara De Ciucis, Renata Colla, Andrea Speciale, Ombretta Garbarino, Olga Bruno, Cinzia Domenicotti

Published Aug 27, 2020 · Vol. 11, No. 37 · pp. 3459-3472

Keywords: tumor angiogenesis, neuroblastoma, vascular mimicry, pyrazolyl-urea derivatives, dihydro-imidazo-pyrazolyl-urea derivatives

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies Review

Fleury Augustin Nsole Biteghe, Neelakshi Mungra, Nyangone Ekome Toung Chalomie, Jean De La Croix Ndong, Jean Engohang-Ndong, Guillaume Vignaux, Eden Padayachee, Krupa Naran, Stefan Barth

Published Aug 26, 2020 · Vol. 11, No. 38 · pp. 3531-3557

Keywords: epidermal growth factor receptor (EGFR), recombinant immunotoxins (ITs), targeted human cytolytic fusion proteins (hCFPs), recombinant antibody-drug conjugates (rADCs), recombinant antibody photoimmunoconjugates (rAPCs)

A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Research Paper

Erryk S. Katayama, Jonathan J. Hue, David L. Bajor, Lee M. Ocuin, John B. Ammori, Jeffrey M. Hardacre, Jordan M. Winter

Published Aug 24, 2020 · Vol. 11, No. 38 · pp. 3489-3501

Keywords: pancreatic cancer, pancreatic ductal adenocarcinoma, clinical trial, novel treatment, drug development

Efavirenz induces DNA damage response pathway in lung cancer Research Paper

Rahaba Marima, Rodney Hull, Zodwa Dlamini, Clement Penny

Published Aug 22, 2020 · Vol. 11, No. 41 · pp. 3737-3748

Keywords: efavirenz, cell cycle, differential gene expression, DNA damage response pathway, lung cancer

ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest Research Paper

Luigi Scotto, Xavier J. Serrano, Kelly Zullo, Cristina Kinahan, Changchun Deng, Ahmed Sawas, Susan Bates, Owen A. O’Connor

Published Aug 18, 2020 · Vol. 11, No. 37 · pp. 3432-3442

Keywords: lymphoma, HDAC inhibitor, ATM inhibitor, p21, cell cycle

NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer Research Paper

Takuma Yotsumoto, Keita Maemura, Kousuke Watanabe, Yosuke Amano, Yoko Matsumoto, Koichi Zokumasu, Takahiro Ando, Masanori Kawakami, Hidenori Kage, Jun Nakajima, Yutaka Yatomi, Takahide Nagase, Daiya Takai

Published Aug 14, 2020 · Vol. 11, No. 39 · pp. 3590-3600

Keywords: antibody-drug conjugates, small cell lung cancer, novel molecular targets, NRXN1, cell adhesion molecule

Targeted CRM1-inhibition perturbs leukemogenic NUP214 fusion proteins and exerts anti-cancer effects in leukemia cell lines with NUP214 rearrangements Research Paper

Adélia Mendes, Ramona Jühlen, Valérie Martinelli, Birthe Fahrenkrog

Published Aug 11, 2020 · Vol. 11, No. 36 · pp. 3371-3386

Keywords: CRM1, NUP214, leukemia, nuclear export, nucleoporin

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers Research Paper

Rod Balhorn, Monique Cosman Balhorn

Published Aug 5, 2020 · Vol. 11, No. 35 · pp. 3315-3349

Keywords: HLA-DR, selective high affinity ligand, SH7139, SH7129, solid cancers

The bromodomain inhibitor IBET-151 attenuates vismodegib-resistant esophageal adenocarcinoma growth through reduction of GLI signaling Research Paper

Annamil Alvarez-Trotta, Zhiqiang Wang, Elena Shersher, Bin Li, Jun Long, Ines Lohse, Claes Wahlestedt, Wael El-Rifai, David J. Robbins, Anthony J. Capobianco

Published Jul 28, 2020 · Vol. 11, No. 33 · pp. 3174-3187

Keywords: IBET-151, esophageal adenocarcinoma, GDC-0449 resistance, patient-derived xenografts, Hedgehog/GLI signaling pathway

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes Review

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine Review

A systematic review and meta-analysis of selected toxicity endpoints of alpelisib Review

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer Research Paper

Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment Research Paper

Simvastatin is a potential candidate drug in ovarian clear cell carcinomas Research Paper

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity Research Paper

Targeting desmoplasia in pancreatic cancer as an essential first step to effective therapy Research Perspective

Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis Research Paper

Small ceramide tames big p53 mutant beast Editorial

Biological evaluation of pyrazolyl-urea and dihydro-imidazo-pyrazolyl-urea derivatives as potential anti-angiogenetic agents in the treatment of neuroblastoma Research Paper

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies Review

A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Research Paper

Efavirenz induces DNA damage response pathway in lung cancer Research Paper

ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest Research Paper

NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer Research Paper

Targeted CRM1-inhibition perturbs leukemogenic NUP214 fusion proteins and exerts anti-cancer effects in leukemia cell lines with NUP214 rearrangements Research Paper

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers Research Paper

The bromodomain inhibitor IBET-151 attenuates vismodegib-resistant esophageal adenocarcinoma growth through reduction of GLI signaling Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes Review

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine Review

A systematic review and meta-analysis of selected toxicity endpoints of alpelisib Review

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer Research Paper

Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment Research Paper

Simvastatin is a potential candidate drug in ovarian clear cell carcinomas Research Paper

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity Research Paper

Targeting desmoplasia in pancreatic cancer as an essential first step to effective therapy Research Perspective

Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis Research Paper

Small ceramide tames big p53 mutant beast Editorial

Biological evaluation of pyrazolyl-urea and dihydro-imidazo-pyrazolyl-urea derivatives as potential anti-angiogenetic agents in the treatment of neuroblastoma Research Paper

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies Review

A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Research Paper

Efavirenz induces DNA damage response pathway in lung cancer Research Paper

ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest Research Paper

NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer Research Paper

Targeted CRM1-inhibition perturbs leukemogenic NUP214 fusion proteins and exerts anti-cancer effects in leukemia cell lines with NUP214 rearrangements Research Paper

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers Research Paper

The bromodomain inhibitor IBET-151 attenuates vismodegib-resistant esophageal adenocarcinoma growth through reduction of GLI signaling Research Paper